12/20
08:19 am
prta
Prothena Co. plc (NASDAQ: PRTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $48.00 price target on the stock, down previously from $84.00.
Low
Report
Prothena Co. plc (NASDAQ: PRTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $48.00 price target on the stock, down previously from $84.00.
12/20
08:16 am
prta
Prothena Co. plc (NASDAQ: PRTA) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $40.00 price target on the stock.
Low
Report
Prothena Co. plc (NASDAQ: PRTA) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $40.00 price target on the stock.
12/19
12:57 pm
prta
Prothena Co. plc (NASDAQ: PRTA) had its price target lowered by analysts at Bank of America Co. from $26.00 to $22.00. They now have a "neutral" rating on the stock.
Low
Report
Prothena Co. plc (NASDAQ: PRTA) had its price target lowered by analysts at Bank of America Co. from $26.00 to $22.00. They now have a "neutral" rating on the stock.
12/19
08:32 am
prta
Roche, Prothena miss main goal in mid-stage trial for Parkinson’s drug [Seeking Alpha]
High
Report
Roche, Prothena miss main goal in mid-stage trial for Parkinson’s drug [Seeking Alpha]
12/19
01:08 am
prta
Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease [Yahoo! Finance]
High
Report
Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease [Yahoo! Finance]
12/19
01:05 am
prta
Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease
High
Report
Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease
11/20
12:04 am
prta
Prothena Co. plc (NASDAQ: PRTA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Prothena Co. plc (NASDAQ: PRTA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/13
10:08 am
prta
Prothena Co. plc (NASDAQ: PRTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $84.00 price target on the stock.
Low
Report
Prothena Co. plc (NASDAQ: PRTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $84.00 price target on the stock.
11/13
09:11 am
prta
Prothena Q3 Earnings Beat Estimates, Pipeline Progress in Focus [Yahoo! Finance]
Low
Report
Prothena Q3 Earnings Beat Estimates, Pipeline Progress in Focus [Yahoo! Finance]
11/12
08:04 pm
prta
Prothena (PRTA) Reports Q3 Loss, Misses Revenue Estimates [Yahoo! Finance]
Low
Report
Prothena (PRTA) Reports Q3 Loss, Misses Revenue Estimates [Yahoo! Finance]
11/12
04:41 pm
prta
Prothena Reports Third Quarter 2024 Financial Results and Business Highlights [Yahoo! Finance]
Medium
Report
Prothena Reports Third Quarter 2024 Financial Results and Business Highlights [Yahoo! Finance]
11/12
04:05 pm
prta
Prothena Reports Third Quarter 2024 Financial Results and Business Highlights
Low
Report
Prothena Reports Third Quarter 2024 Financial Results and Business Highlights
11/5
04:05 pm
prta
Prothena to Report Third Quarter 2024 Financial Results on November 12
Medium
Report
Prothena to Report Third Quarter 2024 Financial Results on November 12
10/18
10:28 am
prta
Prothena: Delays And Data Uncertainty Undermine Case For Investing (Downgrade) [Seeking Alpha]
Low
Report
Prothena: Delays And Data Uncertainty Undermine Case For Investing (Downgrade) [Seeking Alpha]
10/1
08:01 am
prta
Prothena Co. plc (NASDAQ: PRTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $84.00 price target on the stock.
Low
Report
Prothena Co. plc (NASDAQ: PRTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $84.00 price target on the stock.
10/1
08:01 am
prta
Prothena Co. plc (NASDAQ: PRTA) had its price target lowered by analysts at Bank of America Co. from $33.00 to $31.00. They now have a "neutral" rating on the stock.
Low
Report
Prothena Co. plc (NASDAQ: PRTA) had its price target lowered by analysts at Bank of America Co. from $33.00 to $31.00. They now have a "neutral" rating on the stock.
9/30
08:40 am
prta
Prothena Co. plc (NASDAQ: PRTA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
High
Report
Prothena Co. plc (NASDAQ: PRTA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
9/27
04:05 pm
prta
Prothena Announces Leadership Team Updates
High
Report
Prothena Announces Leadership Team Updates